caa a22 4500 606220755 CHVBK 20210128101125.0 cr unu---uuuuu 210128e20151101xx s 000 0 eng 10.1007/s00380-014-0554-z doi (NATIONALLICENCE)springer-10.1007/s00380-014-0554-z Contribution of apolipoprotein A-I to the reduction in high-sensitivity C-reactive protein levels by different statins: comparative study of pitavastatin and atorvastatin [Elektronische Daten] [Shigemasa Tani, Atsuhiko Takahashi, Ken Nagao, Atsushi Hirayama] Recently, investigation may have focused on modification of apolipoprotein A-I (apoA-I) associated with anti-inflammatory effect for the potential prevention of cardiovascular events. The purpose of this study was to evaluate the effects of atorvastatin and pitavastatin on serum apoA-I levels and to investigate the role of apoA-I in the anti-inflammatory effect of statin. We conducted a 6-month, prospective, randomized, open-label study in which we assigned hypercholesterolemic patients to a pitavastatin group (n=52; 2mg/day) or an atorvastatin group (n=52; 10mg/day) to investigate the effects of these two statins on the serum apoA-I levels and serum high-sensitivity C-reactive protein (hs-CRP) levels. There were no significant differences between the two groups in the changes in the low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), or hs-CRP levels, but the change in apoA-I in the pitavastatin group was significantly greater than in the atorvastatin group (5.3 vs. 1.4%; p=0.0001). A stepwise regression analysis revealed that the percent change in (Δ) serum apoA-I level was an independent predictor of the Δ serum hs-CRP (standard correlation coefficient=−0.198; p=0.047). However, there was a significant negative correlation between the Δ apoA-I levels and Δ hs-CRP levels in the pitavastatin group (r=−0.283, p=0.042), but not the atorvastatin group (r=−0.133, p=0.356). The results suggest that the contribution of apoA-I to the reduction in serum hs-CRP levels by these two statins may be different. A decrease in hs-CRP level accompanied by an increase in apoA-I level may be involved in the pleiotropic effects of pitavastatin. Springer Japan, 2014 Atherosclerosis nationallicence Apolipoprotein A-I nationallicence High-sensitivity C-reactive protein nationallicence Inflammation nationallicence Statin nationallicence Tani Shigemasa Health Planning Center, Nihon University School of Medicine, 1-7-3 Kandasurugadai, Chiyoda-ku, 101-0062, Tokyo, Japan aut Takahashi Atsuhiko Health Planning Center, Nihon University School of Medicine, 1-7-3 Kandasurugadai, Chiyoda-ku, 101-0062, Tokyo, Japan aut Nagao Ken Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan aut Hirayama Atsushi Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan aut Heart and Vessels Springer Japan 30/6(2015-11-01), 762-770 0910-8327 30:6<762 2015 30 380 https://doi.org/10.1007/s00380-014-0554-z text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00380-014-0554-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Tani Shigemasa Health Planning Center, Nihon University School of Medicine, 1-7-3 Kandasurugadai, Chiyoda-ku, 101-0062, Tokyo, Japan aut NATIONALLICENCE 700 1- Takahashi Atsuhiko Health Planning Center, Nihon University School of Medicine, 1-7-3 Kandasurugadai, Chiyoda-ku, 101-0062, Tokyo, Japan aut NATIONALLICENCE 700 1- Nagao Ken Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan aut NATIONALLICENCE 700 1- Hirayama Atsushi Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan aut NATIONALLICENCE 773 0- Heart and Vessels Springer Japan 30/6(2015-11-01), 762-770 0910-8327 30:6<762 2015 30 380